C07J 5/003
By a saturated or unsaturated hydrocarbon group including 16-alkylidene substitutes
Official title: {by a saturated or unsaturated hydrocarbon group including 16-alkylidene substitutes}
C07J5/003 (By a saturated or unsaturated hydrocarbon group including 16-alkylidene substitutes) appears on 23 US grants and 17 published applications in this corpus.
Search patents in C07J- Granted patents
- 23
- Published applications
- 17
- Assignees
- 14
- Inventors
- 39
- Latest grant
- 5 Dec 2023
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 2 | 0 |
| 1981 | 2 | 0 |
| 1982 | 2 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 2 | 1 |
| 2013 | 0 | 3 |
| 2014 | 1 | 1 |
| 2015 | 1 | 1 |
| 2016 | 1 | 1 |
| 2017 | 2 | 2 |
| 2018 | 2 | 1 |
| 2019 | 1 | 2 |
| 2020 | 2 | 0 |
| 2021 | 0 | 1 |
| 2022 | 0 | 0 |
| 2023 | 1 | 1 |
| 2024 | 0 | 1 |
| 2025 | 0 | 0 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Non-hormonal steroid modulators of NF-kB for treatment of disease5 Dec 2023US 11,833,159 B2ReveraGen BioPharma, Inc.
- Non-hormonal steroid modulators of NF-kB for treatment of disease8 Dec 2020US 10,857,161 B2ReveraGen BioPharma, Inc.
- Lipid-linked prodrugs22 Sep 2020US 10,780,174 B2The University of British Columbia
- Non-hormonal steroid modulators of NF-kB for treatment of disease19 Feb 2019US 10,206,933 B2ReveraGen BioPharma, Inc.
- Process for the preparation of 17-desoxy-corticosteroids30 Oct 2018US 10,112,970 B2Taro Pharmaceutical Industries Ltd.
- Non-hormonal steroid modulators of nf-kb for treatment of disease3 Sep 2026US 2026/0256810 A1ReveraGen BioPharma, Inc.
- Non-hormonal steroid modulators of nf-kb for treatment of disease29 Aug 2024US 2024/0285650 A1ReveraGen BioPharma, Inc.
- Crystalline forms of vamorolone5 Jan 2023US 2023/0002439 A1
- Non-hormonal steroid modulators of nf-kb for treatment of disease25 Feb 2021US 2021/0052606 A1ReveraGen BioPharma, Inc.
- Lipid-Linked Prodrugs23 May 2019US 2019/0151458 A1The University of British Columbia
Most cited
By later US patents
- 9.alpha.-hydroxy-17-methylene steroids, process for their preparation and their use in the preparation of corticosteroids13US 5,194,602 AGist-Brocades N. V. · 1993
- Non-hormonal steroid modulators of NF-κB for treatment of disease13US 8,207,151 B2Validus Biopharma Inc. · 2012
- Non-hormonal steroid modulators of NF-κB for treatment of disease10US 8,334,279 B2Validus Genetics · 2012
- Non-hormonal steroid modulators of NF-kB for treatment of disease10US 8,673,887 B2ReveraGen BioPharma, Inc. · 2014
- Non-hormonal steroid modulators of NF-κB for treatment of disease8US 9,434,758 B2ReveraGen BioPharma, Inc. · 2016